Module

Mechanism-Based Therapies for the Treatment of Lymphoid Leukemias

Source: Advances in Lymphoproliferative Disease: From Molecular Pathogenesis to Multitargeted Treatment

Mechanism-Based Therapies for the Treatment of Lymphoid Leukemias

Program Director: Alexandra M. Levine, MD

Faculty:

Michael J. Keating, MB BS

CME CREDIT INFORMATION

Release Date: 08/08/08

Expiration Date: 08/07/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.8 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite novel mechanism-based therapies used in the treatment of chronic lymphocytic leukemia
Describe efficacy and safety results from clinical trials enrolling patients with chronic lymphocytic leukemia
Discuss current treatment options used in patients with chronic lymphocytic leukemia

Topics covered include:

Introduction
DNA Repair Inhibitors in CLL
Oxaliplatin, Fludarabine, Ara C, Rituximab Regimen in CLL
Proapoptotic Agents in CLL
CLL Treatments Targeting Bcl2 Homology Domains
Small-Molecule Cyclin Dependent Kinase Inhibitors
Immunomodulatory Agents
Second Generation BCR ABL Tyrosine Kinase Inhibitors
Conclusions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.